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ABSTRACT 
 
Objective: Appearance concerns are common in systemic sclerosis (SSc) and have been linked 
to younger age and more severe disease. No study has examined their association with sex or 
race/ethnicity.  
Methods: SSc patients were sampled from the Scleroderma Patient-centered Intervention 
Network Cohort. Presence of appearance concerns was assessed with a single item, and medical 
and sociodemographic information were collected.  
Results: Of 644 patients, appearance concerns were present in 72%, including 421 of 565 
women (75%), 42 of 79 men (53%), 392 of 550 patients who identified as White (71%), 35 of 41 
who identified as Black (85%), and 36 of 53 who identified as another race/ethnicity (68%). In 
multivariate analysis, women had significantly greater odds of reporting appearance concerns 
than men (odds ratio (OR)=2.97, 95% confidence interval (CI)=1.78-4.95, p<.001). Black 
patients had significantly greater odds of appearance concerns than White patients in unadjusted 
(OR=2.64, 95% CI=1.01-6.34, p=.030), but not multivariate analysis (OR=1.76, 95% CI=0.67-
4.60, p=.250). Compared to a general population sample, appearance concerns were substantially 
more common in SSc, particularly for men across all age groups and for younger women. The 
most commonly reported features of concern were related to the face and head, followed by the 
hands and fingers; this did not differ by sex or race/ethnicity. 
Conclusion: Appearance concerns were common in SSc. Women were substantially more likely 
than men to have appearance concerns. Although non-significant in multivariate analysis, Black 
patients were more likely to have concerns than White patients, likely due to more severe 
changes in appearance.  
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Disfiguring appearance changes, including telangiectasias, hand contractures, skin 
pigmentation changes, digital ulcers, and altered facial features, are common in systemic 
sclerosis (SSc). These appearance changes often affect body parts that are highly visible and that 
play a central role in social interactions, such as the face, mouth, and hands [1-3]. Treatments can 
lessen the impact of some SSc symptoms but do not alleviate manifestations of irreversible tissue 
damage that affect appearance.  
Among individuals with visible differences due to medical illness or injury, there is a 
well-established relationship between the extent and severity of appearance changes and 
psychological outcomes [4, 5]. Consistent with this, in SSc, the presence, severity, and perceived 
noticeability of appearance changes are associated with greater body image dissatisfaction and 
social discomfort, as well as poorer overall psychosocial and psychological functioning [6-12]. 
The association of younger age and greater appearance concerns is also well-established, both 
among people with visible differences and in the general population [4, 13, 14]. Among 2,100 
randomly sampled members of the UK general population, 70% of women and 50% of men 30 
years or younger reported at least one appearance concern compared to 33% of women and 21% 
of men 61 years or older [14]. Younger patients with SSc have also been found to experience 
greater social discomfort related to appearance than older patients [7]. 
No published studies have investigated the degree to which sex and race/ethnicity may be 
associated with appearance concerns in SSc, likely due to the small numbers of men and non-
White patients in most study samples. Among other groups of people with visible differences 
(e.g., skin conditions, burn scarring, limb disfigurement), however, women experience more 
worry about their appearance and greater general distress, social anxiety, and social avoidance 
than men [15-20]. Less is known about the association of race/ethnicity and appearance concerns 
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due to visible differences. One survey of 458 adults with a variety of visible disfigurements 
found that people from non-White racial/ethnic backgrounds experienced significantly greater 
worry about their appearance and heightened concern that their condition was noticeable to 
others than White respondents [20]. This may have been because people with darker skin tones 
are more vulnerable to visible changes in skin pigmentation and report greater psychosocial 
impact compared to individuals with lighter skin tones [21]. In SSc, skin involvement and 
pigmentation changes are more common among Black patients than White patients, whereas 
White patients are more likely to have telangiectasias [22].  
The objective of the present study was to examine the association of sex and race/ethnicity 
with the presence of appearance concerns, controlling for factors that are known to influence 
appearance concerns (e.g., age, disease severity) in a large, international cohort of SSc patients. 
We also compared the percentage of patients with SSc who reported the presence of appearance 
concerns to rates previously published from a UK general population sample, stratified by sex 
and age groups [14]. 
METHODS 
The sample consisted of patients enrolled in the Scleroderma Patient-centered 
Intervention Network (SPIN) Cohort [23] who completed baseline study questionnaires from 
April 2014 through August 2015. Patients were enrolled at 21 SPIN centers in Canada, the USA, 
and the UK. To be eligible for the SPIN Cohort, patients must have a confirmed diagnosis of SSc 
according to the 2013 American College of Rheumatology/European League Against 
Rheumatism classification criteria [24], be ≥ 18 years of age, have the ability to give informed 
consent, be fluent in English or French, and have access and the ability to respond to 
questionnaires via the Internet. The SPIN sample is a convenience sample. Eligible patients are 
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invited by attending physicians or supervised nurse coordinators from SPIN centers to participate 
in the SPIN Cohort, and written informed consent is obtained. The local SPIN physician or nurse 
coordinator completes a medical data form that is submitted online to initiate patient registration. 
After completion of online registration, an automated welcoming email is sent to participants 
with instructions for activating their SPIN account and completing SPIN Cohort measures 
online. SPIN Cohort patients complete outcome measures via the Internet upon enrollment and 
subsequently every three months. Patients who had complete data at their baseline assessment for 
all variables necessary for the planned multivariate analysis were included. The SPIN Cohort 
study was approved by the Research Ethics Committee of the Jewish General Hospital, 
Montréal, Canada and by the research ethics committees of each participating center. 
Sociodemographic Characteristics 
Patients enrolled in the SPIN Cohort provided sociodemographic data, including sex, 
race/ethnicity, age, education level, marital status, and employment status. Response options for 
race/ethnicity differed slightly for patients from Canada, the USA, and the UK, consistent with 
how racial/ethnic status is typically characterized in each country. In the Canadian sample, 
patients could identify as White, Black, Aboriginal, Asian, Latin American, or Arab. In the USA 
sample, patients could identify as White (non-Hispanic), African American or Black, Hispanic or 
Latino, Asian, American Indian/Alaska Native, Native Hawaiian/Other Pacific Islander, or 
Mixed-race. In the UK sample, patients could identify as White, African, or Asian. In the present 
study, racial/ethnic status was collapsed into three categories across Canadian, American, and 
UK samples, consisting of White, Black, or Other. Across countries, responses indicating White 
racial/ethnic status were combined to create one White race/ethnicity category; responses 
indicating Black, African American or Black, or African were combined to create one Black 
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race/ethnicity category; and other responses were combined to create one Other race/ethnicity 
category. 
Disease-related and Medical Characteristics  
SPIN physicians or nurse coordinators provided disease and medical information, 
including time since onset of the first non-Raynaud’s symptom (disease duration); disease 
subtype (limited or diffuse); and presence of telangiectasias, skin pigmentation changes, hand 
contractures, skin thickening on the fingers of both hands, and body mass index (BMI). Limited 
SSc was defined as skin involvement distal to the elbows and knees only, whereas diffuse SSc 
was defined as skin involvement proximal to the elbows and knees, and/or the trunk [25]. 
Telangiectasias were defined as the visible dilation of superficial cutaneous blood vessels that 
collapse upon pressure and fill slowly when pressure is released [24]. Skin pigmentation changes 
included either hyper- or hypo-pigmentation of the skin. In the present study, telangiectasias and 
skin pigmentation changes were coded as present on the body and face, present on the body only, 
or none. Hand contractures, which entail limitations in the range of motion of a joint, secondary 
to tightening around the joint, were measured for small joints on the hands (i.e., proximal 
interphalangeal joints, metacarpals, and/or wrists) and categorized as None/Mild (0-25% 
limitation in range of motion), Moderate (25-50%), or Severe (>50%). Skin thickening on the 
fingers of both hands was defined as skin thickening or hardening extending proximal to the 
metacarpophalangeal joints [22]. 
Presence of Appearance Concerns  
The Derriford Appearance Scale (DAS-24) [26, 27] is a self-report measure of distress 
related to problems with appearance. It assesses social anxiety and avoidance related to self-
consciousness due to appearance. The DAS-24 has an introductory item, not included in the 
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scoring of the measure, that asks, “Is there any aspect of your appearance (however small) that 
concerns you at all?” (yes/no). This item was used as the primary outcome in the present study. 
Published prevalence of appearance concerns using this question is available for the UK general 
population [14], which we used for comparison. In addition, for patients who answer yes to the 
appearance concern question, the DAS-24 includes a further inquiry, “The aspect of my 
appearance about which I am most sensitive or self-conscious is ….” with space for open 
response. s If patients reported more than one aspect of appearance concern, the first listed was 
used. 
Data Analysis 
Descriptive statistics were calculated for all sociodemographic and disease/medical 
variables, including means and standard deviations (SDs) for continuous variables. Chi-square 
tests were used for categorical variables, and a one-way Analysis of Variance was used for 
continuous variables to compare patients on sociodemographic and disease/medical 
characteristics across sex and race/ethnicity categories. For illustrative purposes, Bonferroni-
corrected comparisons were done to assess statistical significance between pairs of race/ethnicity 
groups for variables with statistically significant overall tests. To maintain the family-wise error 
rate < .05, the Bonferroni-corrected α for each of the three subgroup comparisons for each 
variable was .0167. 
The associations of sociodemographic variables (sex, race/ethnicity, age, marital status, 
education level), and disease/medical variables (telangiectasias, skin pigmentation changes, hand 
contractures, skin thickening on fingers, disease subtype, BMI) with the presence of appearance 
concerns were assessed using binary logistic regression. All variables included in the regression 
analysis were selected a priori based on previous research indicating variables likely to relate to 
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appearance concerns in SSc. Discrimination and calibration of the multivariate model were 
assessed with the c-index and Hosmer-Lemeshow goodness-of-fit test statistic, respectively [28]. 
The c-index is the percentage of comparisons where patients with appearance concerns had a 
higher predicted probability of having appearance concerns than patients without appearance 
concerns for all possible pairs where patients were discrepant on outcome variable status. The 
Hosmer-Lemeshow goodness-of-fit statistic is a measure of the accuracy of the predicted number 
of cases of appearance concerns compared to the number of patients who actually reported 
appearance concerns across the spectrum of probabilities. A relatively large p value indicates a 
reasonably good model fit [28]. All analyses were conducted using SPSS (Version 22), and 
statistical tests were two-sided with α < .05. 
The percentage of women and men with SSc who reported appearance concerns was 
compared to levels of appearance concerns reported in a sample from the general UK population 
[14]. The relative risk of reporting appearance concerns was calculated for women and men, 
separately, stratified by age groups. Race/ethnicity data were not provided for the UK population 
sample, thus comparisons for these groups separately could not be conducted. 
RESULTS  
In total, 757 SSc patients completed baseline assessments. There were 717 who answered 
the binary appearance concern item, of whom 644 had data for all variables included in the 
multivariate model and were included in analyses. Of these, 463 (72%) indicated that there was 
an aspect of their appearance that caused them concern. Rates were similar among the 73 patients 
excluded for missing data, with 57 (78%) indicating that there was an aspect of their appearance 
that caused them concern.  
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Sociodemographic and disease/medical characteristics are displayed in Table 1. Mean 
age in the total sample was 55.3 years (Standard Deviation (SD) = 12.1), and the majority of 
patients were White (N = 550, 85%) and married or living as married (N = 471, 73%). Mean 
time since onset of the first non-Raynaud’s symptom was 11.5 (SD = 8.7) years. 
There were 565 (88%) women and 79 (12%) men included. There were no statistically 
significant differences between women and men for any sociodemographic or disease/medical 
variables (see Table 1). There were 41 (6%) Black patients and 53 (8%) patients who identified 
as a member of another racial/ethnic group. As shown in Table 1, White patients were older and 
more likely to be married than Black patients, but less likely to have skin thickening on the 
fingers and to have diffuse SSc (statistically significant, p < .0167). There were also statistically 
significant differences between White and Black patients in presence of telangiectasias and skin 
pigmentation changes. White patients were older and less likely to have diffuse SSc than patients 
from other racial/ethnic groups (statistically significant, p < .0167). There were also statistically 
significant differences in skin pigmentation changes between White patients and those from 
other racial/ethnic groups (see Table 1). 
Among women, 75% (421 of 565) reported appearance concerns, compared to 53% (42 
of 79) of men (p < .001). Across racial/ethnic groups, 85% (35 of 41) of Black patients reported 
appearance concerns, compared to 71% (392 of 550) of White patients and 68% (36 of 53) from 
other racial/ethnic groups (p = .122). 
Of the 463 patients who indicated that there was an aspect of their appearance that 
caused them concern, 444 listed the specific feature of greatest concern. As shown in Table 2, 
the most common category was the face/neck/head/mouth (41%), followed by the hands/fingers 
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(27%). Results were similar for female and male patients and patients classified as White, Black, 
or Other racial/ethnic status.    
As shown in Table 3, on an unadjusted basis, the odds of appearance concerns were 
greater for female patients compared to male patients (OR = 2.70, 95% Confidence Interval (CI) 
= 1.73-4.22, p < .001), and for Black patients versus the reference group, White patients (OR = 
2.64, 95% CI = 1.01-6.34, p = .030). Patients with another racial/ethnic status did not have 
significantly different odds compared to White patients (OR = 0.92, 95% CI = 0.52-1.65, p = 
.788). Other variables that were significantly associated with the presence of appearance 
concerns on an unadjusted basis included younger age, diffuse disease subtype, presence of 
moderate hand contractures, and presence of skin thickening on the fingers.  
In the multivariate analysis, only sex, age, and presence of moderate hand contractures 
were significantly associated with appearance concerns, after controlling for covariates of 
race/ethnicity, BMI, education level, marital status, disease subtype, telangiectasias, 
pigmentation changes, and skin thickening on the fingers. The odds of appearance concerns for 
female patients were significantly greater than for male patients (OR = 2.97, 95% CI = 1.78-
4.95, p < .001). Older patients were also less likely to report appearance concerns than younger 
patients (OR = 0.98 per year, 95% CI = 0.96-0.99, p = .007), equivalent to a reduction of 18% in 
the OR for every 10-year increase in age. The odds of reporting appearance concerns did not 
differ significantly for Black versus White patients (OR = 1.76, 95% CI = 0.67-4.60, p = .250). 
The odds of reporting appearance concerns for patients with moderate hand contractures were 
almost twice those of patients with no or only mild hand contractures (OR = 2.05, 95% CI = 
1.17-3.60, p = .012) (see Table 3). Model fit for the 11 predictors included was less than ideal 
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based on the Hosmer-Lemeshow test (2(8, N = 644) = 10.65, p = .022), and the c-index statistic 
was 0.69. 
As shown in Table 4, rates of appearance concerns were higher, across all age groups, for 
women and men with SSc, compared to women and men from the general UK population sample 
(14). The relative risk of reporting appearance concerns among SSc patients compared to the 
general population was greater for men than for women across age groups. For both women and 
men, the relative risk was substantially higher among older patients. 
DISCUSSION  
The main findings of this study were that women with SSc were substantially more likely 
than men to report appearance concerns, controlling for sociodemographic and disease/medical 
variables. Black racial/ethnic group membership was significantly associated with appearance 
concerns at the bivariate level; however, the association was not statistically significant after 
accounting for the influences of other sociodemographic and disease/medical variables. 
Consistent with findings from previous studies, older age was significantly associated with 
reduced odds of appearance concerns. Among disease variables, moderate hand contractures 
were significantly associated with greater odds of appearance concerns. Compared to data from a 
general population sample, both women and men with SSc were more likely to report appearance 
concerns, although the relative risk was higher for men with SSc compared to women. In 
addition, for both women and men, the relative risk was substantially higher, compared to the 
general population, among older patients than among younger patients. The most commonly 
reported features of concern were related to the face and head, followed by the hands and 
fingers; this did not differ by sex or race/ethnicity.  
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The finding that female SSc patients had greater odds of experiencing appearance concerns 
is consistent with previous research on the relationship between sex and visible differences, 
which has highlighted that women tend to experience greater distress, social anxiety, and 
difficulty adjusting to disfiguring appearance changes than men [16-18]. Although 85% of Black 
patients reported appearance concerns compared to 71% of White patients, race/ethnicity was not 
independently associated with appearance concerns in the multivariate analysis. It is possible that 
the small number of Black people in the study could explain the non-significant result. This 
finding may also have occurred because Black patients tended to be younger, have diffuse 
disease, and have greater pigmentation changes and skin thickening on the fingers compared to 
White patients, as these are all factors associated with appearance concerns.  
Although men with SSc were less likely to report appearance concerns than women with 
the disease, men with SSc had a greater relative risk of appearance concerns compared to the 
general population sample than women. In both SSc and the general population, women are more 
likely than men to have appearance concerns, but the increase in appearance concerns is much 
greater for men with SSc. A similar phenomenon can be seen with respect to age. For both 
women and men in the general population, the proportion of people with appearance concerns 
drops substantially in older groups, particularly for people aged 61 and older. The proportion 
also diminishes across age groups for people with SSc, but much less dramatically, and in SSc, 
older people are more likely to report appearance concerns compared to the general population, 
where worries about appearance have mostly subsided among older adults. 
The finding that the majority of patients across sexes and race/ethnicities listed the face 
and head body regions as the primary feature that caused them concern, followed by the hands 
and fingers, is consistent with previous research in SSc, which has reported that appearance 
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changes to visible and socially relevant body regions are common and of the greatest distress to 
patients [2, 6, 7, 9, 12]. While the categories of appearance concern in the present study were 
broad, results showed that the general types of appearance concerns reported by patients were 
fairly consistent across sex and racial/ethnic groups. 
The present study has limitations that should be considered in interpreting results. First, the 
SPIN Cohort constitutes a convenience sample of SSc patients receiving treatment at SPIN 
recruiting centers, and patients at these centers may differ from those in other settings. SSc 
patients in the SPIN Cohort also complete questionnaires online, which may further limit the 
generalizability of findings. An additional limitation relates to the nature of disease 
characteristics included in the analyses. Specifically, the majority of the variables consisted of 
fairly crude indicators of either the presence or absence of a particular disease factor and did not 
provide a measure of severity. This may have reduced the ability to identify any associations, if 
present, between the severity of visible differences from the disease and the presence of 
appearance concerns. An additional limitation is that the sample sizes of Black patients and those 
who self-identified as members of another racial/ethnic group were small. These limitations may 
have been reflected in the model fit statistics, which were less than ideal [28]. It is also possible 
that the relatively limited information obtained from the predictive model was due to the 
dichotomous outcome variable. Most patients reported the presence of appearance concerns; 
however, measuring appearance concerns may not be something easily categorized as present or 
absent, and thus, the study results may differ if a more robust measure of appearance concerns 
were used. Additionally, the general population sample comparison was done with the only 
general population data that were currently available. While it was useful to contextualize 
patterns of appearance concerns among patients with SSc, the degree of actual differences may 
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have been influenced by factors not considered in the present analysis. Another limitation is that 
the categories for reporting features of concern that were used in the present study were 
somewhat broad and non-specific, which did not allow for a detailed description of the features 
listed by patients. Nonetheless, they provided a general understanding of the common types of 
appearance concerns among patients and underlined that those most important do not vary 
substantially across sex or racial/ethnic groups. Finally, we used self-reported race/ethnicity 
classifications. Race/ethnicity is a complex construct that may reflect sociocultural aspects of 
experience as much as biological aspects. Furthermore, the Other race/ethnicity category allowed 
us to separate out people who did not identify as White or Black, but its composition was 
heterogeneous and not necessarily informative in relation to the experience of any patient or 
group of patients classified in the Other group. 
In sum, female SSc patients had significantly higher odds of reporting appearance 
concerns than male patients. Although Black SSc patients had higher odds of experiencing 
appearance concerns than White patients on an unadjusted basis, this result was not statistically 
significant when accounting for the influence of other sociodemographic and disease/medical 
characteristics. It may be the case that greater appearance concerns among Black patients reflect 
more significant appearance changes, such as skin involvement, including pigmentation changes. 
Both women and men with SSc were more likely to report appearance concerns than general 
population survey respondents. The difference in reporting of appearance concerns between SSc 
patients and the general population was greatest for men and for older patients. In both of these 
cases, rates in the general population were relatively low for these groups, but much less so in 
SSc. Despite differences in overall rates, across groups defined by sex or race/ethnicity, the most 
commonly reported features of appearance concern related to the face and head regions, followed 
  19 
by the hands and fingers. Replications of the current study with larger samples of Black and 
other racial/ethnic groups are needed. In addition, future studies should include assessment of 
appearance concerns with a continuously measured outcome variable or one that explores 
multiple domains of appearance concerns, as well as include factors, such as disease duration and 
disease and serological subtype, to explore their potential impact on appearance concerns. 
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Table 1. Sociodemographic and Disease Characteristics (N = 644)  




























Age (years),  
mean ± SD 
 
55.3 ± 12.1 56.5 ± 11.5
a,b




<.001  55.1 ± 12.0 56.2 ± 12.8 .462 
Education >12 years,  
n (%) 
 
512 (79.5) 434 (78.9) 33 (80.5) 45 (84.9) .579 451 (79.8) 61 (77.2) .591 
Currently employed  











married, n (%)  
 




 37 (69.8) .003 412 (72.9) 59 (74.7) .741 
Time since onset of 
first non Raynaud’s 
symptoms (years), 








 10.2 ± 7.8
i





Body Mass Index 
(BMI) mean ± SD 
 
26.04 ± 6.12 26.14 ± 6.14 26.14 ± 6.84 24.97 ± 5.33 .413  26.02 ± 6.26 26.19 ± 5.00 .816 
Patients with diffuse 
SSc, n (%) 
 






<.001 226 (40.0) 32 (40.5) .971 
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20 (37.7)  153 (27.1) 30 (38.0)  








 18 (34.0)  262 (46.4) 36 (45.6)  
Body only,  
n (%) 
 






















 385 (68.1) 53 (67.1)  
Body and face,  
n (%) 






 89 (15.8)  16 (20.3)  












91 (16.1) 10 (12.7)  
Hand contractures
 
    .898   .988 
No/mild (0-25%),  
n (%) 




121 (18.8) 102 (18.5) 7 (17.1) 12 (22.6)  106 (18.8) 15 (19.0)  
Severe (>50%),  
n (%) 
 
35 (5.4) 30 (5.5) 3 (7.3) 2 (3.8)  31 (5.5) 4 (5.1)  
Skin thickening on 
fingers, n (%) 
 




 36 (67.9) .004 311 (55.0) 49 (62.0) .242 
  27 
 
Abbreviations: SD = standard deviation. 
 
a
White patients statistically significantly different from Black patients. 
b
White patients statistically significantly different from patients from another racial/ethnic group. 
c
Sample size based on
 
N = 643. 
d
Sample size based on
 
N = 549. 
e
Sample size based on N = 78.  
f
Sample size based on N = 595.  
g
Sample size based on N = 510.  
h
Sample size based on N = 40. 
i
Sample size based on N = 45. 
j
Sample size based on N = 519. 
k











.122 421 (74.5) 42 (53.2) <.001 
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Feature       
Body Area-related       
Face/mouth/head/
neck 
180 (40.5) 149 (40.5) 14 (40.0) 17 (41.5) 159 (41.2) 21 (36.2) 
Hands/fingers 119 (26.8) 103 (28.0) 7 (20.0) 9 (22.0) 99 (25.6) 20 (34.5) 
Arms 5 (1.1) 3 (0.8) 1 (2.9) 1 (2.4) 5 (1.3) 0 
Chest/stomach 9 (2.0) 9 (2.4) 0  0 8 (2.1) 1 (1.7) 
Legs/feet 13 (2.9) 12 (3.3) 1 (2.9) 0 12 (3.1) 1 (1.7) 
Skin-related       
Telangiectasias 
(any) 
33 (7.4) 28 (7.6) 1 (2.9) 4 (9.8) 26 (6.7) 7 (12.1) 
Skin pigmentation 
changes (any) 
12 (2.7) 9 (2.4) 1 (2.9) 2 (4.9) 10 (2.6)  2 (3.4) 
  29 
Skin tightening or 
hardening 
7 (1.6) 5 (1.4) 1 (2.9) 1 (2.4) 5 (1.3) 2 (3.4) 
Skin 
unspecified/other 
20 (4.5) 16 (4.3)     1 (2.9) 3 (7.3) 17 (4.4) 3 (5.2) 
Weight-related       
Loss 4 (0.90) 3 (0.8) 1 (2.9) 0 4 (1.0) 0 
Gain/bloating/ 
swelling 
22 (5.0) 17 (4.6) 2 (5.7) 3 (7.3) 22 (5.7) 0 
Unspecified 20 (4.5) 14 (3.8) 5 (14.3) 1 (2.4) 19 (4.9) 1 (1.7) 
Total 444 (100.0) 368 (100.0) 35 (100.0) 41 (100.0) 386 (100.0) 58 (100.0) 
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Table 3. Unadjusted and Adjusted Comparisons of Appearance Concerns across Sociodemographic and Disease Variables  
 
Variable Unadjusted  



















Other 0.92 (0.52-1.65) .788 0.59 (0.31-1.14) .117 
Age 0.97 (0.96-0.98) <.001 0.98 (0.96-0.99) .007 
Female sex 2.70 (1.73-4.22) <.001 2.97 (1.78-4.95) <.001 
Education  12 years 0.69 (0.47-1.02) .063 0.74 (0.48-1.14) .174 
Not married/living as married  1.36 (0.92-2.00) .121 1.05 (0.68-1.60) .841 
BMI
 
1.00 (0.92-1.10) .951 1.01 (0.98-1.05) .421 
Diffuse disease subtype  1.76 (1.24-2.50) .002 1.18 (0.76-1.83) .456 
Telangiectasias (reference = none)     
Body and face 0.81 (0.54-1.22) .313 1.48 (0.89-2.47) .136 
Body only 0.70 (0.44-1.09) .116 1.20 (0.77-1.86) .420 
Pigmentation changes      
  31 
(reference = none) 
Body and face 1.58 (0.96-2.58) .071 0.91 (0.52-1.57) .730 
Body only 1.50 (0.92-2.47) .108 1.02 (0.51-2.06) .947 
Hand contractures (reference = 
none/mild) 
    
Moderate 2.33 (1.41-3.86) .001 2.05 (1.17-3.60) .012 
Severe 2.03 (0.88-4.70) .099 1.96 (0.75-5.15) .170 
Skin thickening on hands 1.64 (1.18-2.28) .003 1.48 (1.00-2.19) .050 
 
Abbreviations: OR = odds ratio; CI = confidence interval; BMI = Body Mass Index.  
 
a
Adjusted for age, sex, race/ethnicity, education level, marital status, disease subtype, telangiectasias, pigmentation changes, hand 
contractures, and skin thickening on fingers.   
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Table 4. Proportion of Women and Men who Reported Appearance Concerns Based on Age in General Population and 
SPIN Samples 
 
 General Population 
Sample (n, %)
a 
SPIN Sample  
(n, %) 
Relative Risk 
SPIN / General 
Population (95% CI) 
Women    
Age bands (years)     
18-40 367/537 (68) 50/60 (83) 1.22 (1.07-1.38) 
41-50 139/226 (62) 80/101 (79) 1.29 (1.12-1.49) 
51-60 151/240 (63) 145/183 (79) 1.26 (1.11-1.42) 
61+  58/174 (33) 146/221 (66) 1.98 (1.57-2.50) 
Men     
Age bands (years)    
18-40 152/341 (45)  5/9 (56) 1.25 (0.69-2.26) 
41-50 69/170 (41)  8/11 (73) 1.79 (1.20-2.69) 
51-60 49/202 (24) 12/22 (55) 2.25 (1.43-3.54) 
61 +  45/218 (21) 17/37 (46)  2.23 (1.44-3.44) 
 
a
Based on values reported in Harris and Carr, 2001 (14).  
 
